Synovial sarcoma (SS), an often lethal sarcoma occurring predominantly in young adults, is defined by a specific chromosomal translocation, t(X;18), which fuses the SYT gene on chromosome 18 to either the SSXl or the SSX2 gene on chromosome X. The SYT-SSX fusion oncoprotein functions as aberrant transcriptional protein that SYT-SSX exerts its transcriptional effects by interacting with histone-modifying enzymes, leading to a deregulation of epigenetic control of gene expression. The present proposal brings together expertise in fundamental histone code biology with experience in synovial sarcoma cell line- and human tissue-based translational research to develop a deeper understanding of SYT-SSX-dependent histone code alterations that could lead to more rational, more precisely targeted, and, hopefully, more effective epigenetic therapy for synovial sarcoma. The proposed work addresses the central role of SYTSSX- dependent epigenetic alterations in the biology of synovial sarcoma from three complementary perspectives: mechanistic (Aim 1), global genomic (Aim 2), and preclinical (Aim 3). Certain cancers are thought to arise from genetic rearrangements that join separate genes to produce new fusion genes with abnormal functions. The SYT-SSX fusion gene in synovial sarcoma is such a gene. Understanding and targeting the biological mechanisms used by these cancer-causing fusion genes can lead to effective therapeutics, as exemplified by imatinib targeting BCR-ABL in chronic myelogenous leukemia and all-trans retinoic acid targeting PML-RARa in acute promyelocytic leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140146-05
Application #
8712172
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
5
Fiscal Year
2014
Total Cost
$216,569
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Bennett, Jennifer A; Braga, Ana C; Pinto, Andre et al. (2018) Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors. Am J Surg Pathol 42:1370-1383
Kao, Yu-Chien; Fletcher, Christopher D M; Alaggio, Rita et al. (2018) Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol 42:28-38
Zhang, Jennifer Q; Zeng, Shan; Vitiello, Gerardo A et al. (2018) Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 6:434-447
Fittall, Matthew W; Mifsud, William; Pillay, Nischalan et al. (2018) Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 9:2150
Antonescu, Cristina R; Agaram, Narasimhan P; Sung, Yun-Shao et al. (2018) A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions. Am J Surg Pathol 42:553-560
Katabi, Nora; Xu, Bin; Jungbluth, Achim A et al. (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72:285-293
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Dickson, Brendan C; Antonescu, Cristina R; Argyris, Prokopios P et al. (2018) Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. Am J Surg Pathol 42:1297-1305

Showing the most recent 10 out of 169 publications